NCT02158091 2026-02-13
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT05044039 2026-02-02
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03961672 2026-01-05
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03534323 2025-08-14
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting